Jubilant Pharmova (BOM:530019) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530019 Jubilant Pharmova Ltd BOM:530019
72 GF Score
Price ₹962.00
GF Value ₹1,065.97
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Jubilant Pharmova Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Jubilant Pharmova's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

BOM:530019 vs ZTS, UTHR: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jubilant Pharmova Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Jubilant Pharmova's Margin of Safety % (DCF Dividends Based) falls into.


BOM:530019
72GF Score
Jubilant Pharmova Ltd BOM:530019
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?

Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued. The current stock price of ₹962.00 is trading 9.8% below its estimated GF Value™ of ₹1,065.97. GuruFocus considers Jubilant Pharmova to be Modestly Undervalued.

Key valuation signals for BOM:530019:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: ₹1,065.97 vs. price of ₹962.00 (9.8% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jubilant Pharmova Business Description

Other Exchanges JUBLPHARMA:India
Address 1A, Sector 16A, Noida, UP, IND, 201301
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
72GF Score

Get the complete analysis for BOM:530019

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹962.00
Price
₹1,065.97
GF Value